Mizuho Has Lowered Expectations for LifeMD (NASDAQ:LFMD) Stock Price

LifeMD (NASDAQ:LFMD) had its price target dropped by stock analysts at Mizuho from $7.00 to $6.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho‘s price target would indicate a potential upside of 173.35% from the company’s previous close.

LFMD has been the subject of several other reports. Lake Street Capital set a $5.00 target price on shares of LifeMD in a report on Thursday, August 6th. BTIG Research cut their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of LifeMD in a research report on Thursday, September 17th. Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a research report on Monday, November 2nd. Finally, B. Riley Financial assumed coverage on shares of LifeMD in a report on Friday, September 11th. They issued a “buy” rating and a $8.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, LifeMD currently has an average rating of “Moderate Buy” and a consensus price target of $7.14.

LifeMD Price Performance

LifeMD stock traded up $0.54 during mid-day trading on Friday, reaching $2.19. The stock had a trading volume of 6,142,984 shares, compared to its average volume of 944,039. The company has a market capitalization of $105.80 million, a price-to-earnings ratio of -36.58 and a beta of 2.19. The company has a 50-day moving average price of $2.60 and a two-hundred day moving average price of $3.57. LifeMD has a one year low of $1.60 and a one year high of $5.38.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $44.63 million for the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a negative net margin of 0.25% and a negative return on equity of 139.69%. On average, equities research analysts anticipate that LifeMD will post -0.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeMD

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its position in LifeMD by 10.1% during the first quarter. Bank of America Corp DE now owns 48,703 shares of the company’s stock valued at $176,000 after acquiring an additional 4,465 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of LifeMD by 2.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 246,586 shares of the company’s stock valued at $1,018,000 after purchasing an additional 5,651 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of LifeMD in the 2nd quarter worth approximately $25,000. Chapin Davis Inc. bought a new position in shares of LifeMD in the 3rd quarter worth approximately $29,000. Finally, Corient Private Wealth LP bought a new position in shares of LifeMD in the 2nd quarter worth approximately $63,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

Top LifeMD Stories

Here are a few of the latest stories about LFMD:

• Positive Sentiment: LifeMD reported a third-quarter loss of $0.11 per share, narrower than the expected $0.14 loss. Adjusted EBITDA also improved by about $3.1 million sequentially, to a loss of roughly $0.4 million, as the company reduced marketing and other non-clinical expenses. LifeMD Q3 2026 results
• Neutral Sentiment: Lake Street Capital lowered its price target from $5 to $3 but kept a Buy rating; Mizuho cut its target from $7 to $6 and maintained an Outperform rating. The retained positive ratings offer support, though both target reductions reflect more cautious expectations. Analyst rating and price target update
• Negative Sentiment: Revenue was $44.6 million, below analysts’ $48.8 million estimate. LifeMD also forecast fourth-quarter revenue of $46–$49 million, versus consensus of $61.4 million, and full-year 2026 revenue of $188–$191 million, versus $207.6 million expected. The shortfall in guidance may weigh on investor expectations for near-term growth. LifeMD Q3 2026 results and guidance

About LifeMD

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.